It has been considered that the risk-benefit of terfenadine 6 mg/ ml oral suspension formulations is acceptable and the Marketing Authorisations should be maintained provided that: -the Summaries of Product Characteristics (SPCs) are revised with emphasis on contraindications due to hepatic or cardiac diseases and pharmacokinetic or pharmacodynamic interactions between terfenadine and other substances as stated in Annex I.